Olverembatinib
Small molecule targets ABL1, FGFR1 via inhibition
Trials 34 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT07493161 Background | Apr 2026 → Mar 2028 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05594758 Background | — | — | Ascentage Pharma Group Inc. | Available | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | olverembatinib | “Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label,...” PMID 35982483 ↗ Aug 202229“Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia” PMID 35982483 ↗ Aug 2022 |
| Known as | [14C] HQP1351 | “A Single-center, Open-label, Single-dose Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C] HQP1351 After a Single Oral 30mg (100µCi) Dose in...” NCT04126707 ↗ |
| Known as | D-824 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2316582 ↗ |
| Known as | D-824 DIMESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2316582 ↗ |
| Known as | GZD-824 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2316582 ↗ |
| Known as | GZD-824 DIMESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2316582 ↗ |
| Known as | HQP-1351 DIMESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2316582 ↗ |
| Known as | HQP1351 | “This phase II trial studies how well the combination of based decitabine and olverembatinib（HQP1351)chemotherapy work for the treatment of blast phase or accelerated phase...” NCT05376852 ↗8“Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label,...” PMID 35982483 ↗ Aug 2022 “This is a Global, Multi-center, Open-label Randomized and Registrational Phase 3 Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia” NCT06423911 ↗ “Named Patient Program for Olverembatinib (HQP1351)” NCT05594758 ↗ |
| Known as | Olverembatinib dimesylate | “HQP1351( Olverembatinib dimesylate)” NCT05604755 ↗ |
| Known as | OVB | “All Ph+-ALL patients will uniformly use the 3rd generation of TKI olverembatinib (OVB) instead of dasatinib throughout the regimen.” NCT07152041 ↗ |
| Action | Inhibit | “Olverembatinib is a new potent BCR-ABL1 TKI” PMID 35982483 ↗ Aug 2022 |
| Modality | Small molecule | “Olverembatinib is a new potent BCR-ABL1 TKI” PMID 35982483 ↗ Aug 2022 |
| Route | Oral | “HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.” NCT03594422 ↗ |
| Target | ABL1 | “Olverembatinib is a new potent BCR-ABL1 TKI with preclinical activity against T315I-mutated CML.” PMID 35982483 ↗ Aug 2022 |